Showing 3411-3420 of 4063 results for "".
- Study: AMD Strongly Associated With Heart Disease and Strokehttps://modernod.com/news/study-blinding-eye-disease-is-strongly-associated-with-heart-disease-and-stroke/2480958/Patients with a specific form of age-related macular degeneration (AMD) are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai. This study, published in the July issue of Retina, is the first t
- Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiologyhttps://modernod.com/news/nicox-announces-publication-of-ncx-470-results-demonstrating-improvements-to-ocular-hemodynamics-and-retinal-cell-physiology-1/2480951/Nicox SA announced that the results from studies on the beneficial effects of NCX 470 in a nonclinical model of endothelin-1 (ET-1)-induced ischemia/reperfusion damage of the optic nerve head and retina have been published online in the peer-reviewed Journal of Ocular Pharmacology and Therape
- SAV-IOL Continues Progress on Electronic IOL Projecthttps://modernod.com/news/sav-iol-continues-progress-on-electronic-iol-project/2480946/SAV-IOL (Swiss Advanced Vision) provided an update on its progress toward making the first active, electronic IOL through their R-TASC Project. SAV-IOL first launched the R-TASC Project idea in 2018. "Current IOLs on the market suffer
- Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabeticshttps://modernod.com/news/ocuphire-granted-new-us-patent-for-late-stage-oral-drug-candidate-apx3330-for-use-in-diabetics/2480941/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued a new patent extending expiry and broadening coverage of the company’s late-stage oral product candidate, APX3330, for diabetic eye disease. In addition, a new publication supporting the nov
- Oyster Point Pharma Announces Restructuring Plan to Reduce Costshttps://modernod.com/news/oyster-point-pharma-announces-operating-expense-streamlining-plan/2480938/Oyster Point Pharma announced it will implement an operating expense streamlining plan that will include a reduction of employee and non-employee expenses across the organization. The company plans to continue to drive the launch of Tyrvaya with approximately 150-200 fie
- BRIM Biotechnology Enters Trading in Taiwanhttps://modernod.com/news/brim-biotechnology-enters-otc-trading-in-taiwan/2480926/BRIM Biotechnology has entered OTC trading in Taiwan on June 23, 2022. Established in 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. BRIM has several novel drug products
- Nanodropper Announces Growth in Partnerships and Availabilityhttps://modernod.com/news/nanodropper-announces-increases-in-partnerships-and-availability/2480921/Nanodropper, a volume-reducing adaptor for eye drop bottles, announced major growth over the last 12 months, including an 832% increase in clinic partnerships, expanding to more than 840 clinic locations since June of 2021. Nanodropper has also more than doubled its team as it finalized rese
- Rayner Acquires Stake in Sustainable Surgical Instrument Belgian Manufacturer Hasa Optixhttps://modernod.com/news/rayner-acquires-stake-in-sustainable-surgical-instrument-belgian-manufacturer-hasa-optix/2480900/Rayner announced that it has entered into a commercial partnership and concurrently acquired a stake in Hasa Optix, a Brussels-based manufacturer of single use ophthalmic surgical instruments and instrument sets. The investment closed June 7, 2022. Financial terms of the deal
- NIH: Gene Therapy for Rare Eye Disease Safe But Lacks Efficacy in Early Trialhttps://modernod.com/news/nih-gene-therapy-for-rare-eye-disease-safe-but-lacks-efficacy-in-early-trial/2480896/A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose. LHON affects the optic nerve, which carries vi
- Oertli Expands its Direct Distribution Networkhttps://modernod.com/news/oertli-expands-its-direct-distribution-network/2480889/Oertli Instrumente acquired the Swiss distributor Domedics AG and integrated the company as of June 1 into their global brand. Terms of the deal were not disclosed. In September 2021, Oertli Instrumente took over the majority of shares in Domedics, a Switzerland-base